

ISSUE @ A GLANCE



Updates on prevention: obesity, ezetimibe, PCSK9, and HIV infection

T.F. Lüscher

3545

CardioPulse

Quality indicators for acute myocardial infarction

F. Schiele

3549

The ESC Heart Failure Association postgraduate course in heart failure

S. Paolillo and C. Minoia

3551

Two weeks at Harvard, for two European heart failure trainees

C. Minoia and S. Paolillo

3553

Zurich International Symposium on Arrhythmogenic Right Ventricular Cardiomyopathies

F. Duru and C. Brunckhorst

3555

Cardiologists of Tomorrow, Austria

K. Ablasser and M. Wallner

3556

Ron T van Domburg PhD retirement

3558

Christmas greetings 2016 from the *European Heart Journal*

3559

REVIEWS

Controversies in cardiovascular medicine

Obesity and cardiovascular disease: friend or foe?

S.H. Kim, J.-P. Després, and K.K. Koh

3560

Prevention


Testosterone: a hormone preventing cardiovascular disease or a therapy increasing cardiovascular events?

B. Gencer and F. Mach

3569

FASTTRACK CLINICAL

Acute coronary syndromes



The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial

A. Eisen, C.P. Cannon, M.A. Blazing, E.A. Bohula, J.-G. Park, S.A. Murphy, J.A. White, R.P. Giugliano, and E. Braunwald, on behalf of the IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial) Investigators

3576

Editorial	Improving cardiovascular outcomes by intensifying low density lipoprotein lowering therapy in high-risk patients <i>D.S. Jacoby and D.J. Rader</i>	3585
Lipids	Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial <i>P.M. Moriarty, K.G. Parhofer, S.P. Babirak, M.-A. Cornier, P.B. Duell, B. Hohenstein, J. Leebmann, W. Ramlow, V. Schettler, V. Simha, E. Steinhagen-Thiessen, P.D. Thompson, A. Vogt, B. von Stritzky, Y. Du, and G. Manvelian</i>	3588
Editorial	ODYSSEY ESCAPE: is PCSK9 inhibition the Trojan Horse for the use of lipoprotein apheresis in familial hypercholesterolaemia? <i>G.F. Watts and C. Stefanutti</i>	3596

META-ANALYSIS

Comparative safety and efficacy of statins for primary prevention in human immunodeficiency virus-positive patients: a systematic review and meta-analysis <i>S. Gili, W. Grosso Marra, F. D'Ascenzo, E. Llonni, A. Calcagno, M. Cannillo, F. Ballocca, E. Cerrato, M. Pianelli, U. Barbero, M. Mancone, J.J. DiNicolantonio, C.J. Lavie, P. Omedè, A. Montefusco, S. Bonora, M. Gasparini, G. Biondi-Zoccali, C. Moretti, and F. Gaita</i>	3600
--	------

CLINICAL RESEARCH

Prevention and epidemiology Effects of paediatric HIV infection on childhood vasculature <i>N.S. Idris, D.E. Grobbee, D. Burgner, M.M.H. Cheung, N. Kurniati, and C.S.P.M. Uiterwaal</i>	3610
--	------

CARDIOVASCULAR FLASHLIGHTS

Massive hydropneumopericardium after pericardial drain removal <i>I. Dregoes, A. Iancu, A. Štef, and A. Molnar</i>	3617
Repetitive vasospasm as a cause of plaque rupture and myocardial infarction <i>N. Ryan, N. Gonzalo, A. Freitas-Ferraz, P. Martinez, and J. Escaned</i>	3619



Open Access Paper



For the podcast associated with this article, please visit <https://academic.oup.com/eurheartj/pages/Podcasts>



Visit EHJ's mobile site
<https://academic.oup.com/eurheartj>



www.eurheartj.org